Eiger BioPharmaceuticals Inc. Company Profile | StatInvestor

Health Care & Life Sciences » Biotechnology | Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals Inc.
Stock Exchange	Frankfurt Stock Exchange
EPS	-
Market Cap	-
Shares Outstanding	14.24 M
Public Float	6.83 M

Eiger BioPharmaceuticals Inc.
Stock Exchange	NASDAQ Stock Market
EPS	$3.84
Market Cap	$194.53 M
Shares Outstanding	24.44 M
Public Float	15.86 M

Profile

Address	2155 Park Boulevard Palo Alto California 94306 United States
Employees	-
Website	http://www.eigerbio.com
Updated	07/08/2019
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for orphan diseases. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex. The company was founded by David A.

Financials

David A. Cory

President, Chief Executive Officer & Director

David Apelian

COO, Director & Executive Medical Officer